Strategic Advisory Group of Experts on Immunization (SAGE) - October 2014

21 – 23 October 2014

The SAGE meeting of 21-23 October 2014 took place in the EB room at the WHO headquarters in Geneva. Available on this site you will find meeting information and background reading materials as well as presentations made at the meeting. The conclusions and recommendations of SAGE meeting are published in the WHO Weekly Epidemiological Record in English and French within two months of each SAGE meeting.

Meeting materials

Related

Background documents and presentations

SAGE Yellow Book - October 2014

 

Session: Report from IVB director

Background documents

Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations

SAGE tracking record of recommendations and action points

2014 Update on the Regional Immunization Program of the Americas

Technical Advisory Group on Vaccine-preventable Diseases (TAG) XXII Meeting Washington DC, 1-2 July, 2014

5th South-East Asia Regional technical Advisory Group on Immunization (SEAR-ITAG) Meeting recommendations (August 2014)

23rd Meeting of the technical advisory group (TAG) on Immunization and vaccine preventable diseases in the Western Pacific Region, Manila, 17-20 June 2014. Conclusions and recommendations

WHO Media centre: Ebola situation assessment - 1 October 2014

Presentations

Global report including key updates and challenges from regions-P. Duclos

Update on the Ebola outbreak and experimental Ebola vaccines-D. Wood


Show less Show more
Session: report from GAVI
Show less Show more

Session: Reports from other Advisory Committees on Immunization

Show less Show more

Session: GVAP progress report

Show less Show more

Session: Japanese encephalitis vaccines

Show less Show more

Session: Meningococcal A conjugate vaccine impact and routine immunization schedule in infants and young children

Background documents

Meningococcal A conjugate vaccine roll-out in the African meningitis belt. Summary update prepared by the Meningitis Vaccine Project & partners. SAGE, October 2014

Modelling long-term vaccination strategies with MenAfriVac® in the African meningitis belt. Executive summary prepared for SAGE, October 2014

Results from MenA vaccine randomized controlled trials in infants and young children - Executive summary for SAGE

Meningococcal vaccines: WHO position paper, November 2011

WHO Guideline on Meningitis Outbreak response in sub-Saharan Africa Appendix A : Changing epidemiology in the meningitis belt

WHO immunological basis for immunization Series: Module 15: Meningococcal Disease

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

Report from WHO Global Advisory Committee on Vaccine Safety, 11-12 June 2014

Please refer to pp. 329-331: "Meningococcal A conjugate vaccine during pregnancy"

Presentations

Why are we reviewing the evidence on meningococcal A conjugate vaccine and what are the questions for SAGE today?-K. O'Brien

Rollout of the meningococcal A conjugate vaccine through mass vaccination campaigns in countries of the meningitis belt-M. Djingarey

Results from clinical trials in infants and young children, safety in pregnancy, and review of routine coverage data-A. Hodgson

Modeling of strategies for routine use of the meningococcal A conjugate vaccine, in the context of a dynamic vaccination program, and future evidence needs to inform vaccine policy-C. Trotter

What are the preferred schedules for meningococcal A conjugate vaccine for infants and young children living in countries of the African meningitis belt?-K. O'Brien


Show less Show more

Session: Global polio eradication initiative

Background documents

9th Meeting of the SAGE Polio Working Group (July 2014):Conclusions and recommendations

OPV Cessation: Protocol for a global coordinated switch from trivalent OPV to bivalent OPV. Note: the latest version of the switch Guidelines for National Operational Plans and other supporting materials are available here

Independent monitoring board of the global polio eradication initiative, May 2014 report

Working draft GAPIII: WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of routine OPV use.

mOPV2 stockpile policy for type 2 outbreak response in the post cessation phase.

Plan for tOPV campaigns immediately prior to tOPV to bOPV switch: draft risk assessment concept note

Protocol for notification, risk assessment, and response following detection of poliovirus type 2 following globally-coordinated cessation of serotype 2-containing oral polio vaccine

Presentations

Introduction: Issues for SAGE decisions and discussions-B. Aylward

Major decisions for the OPV2 withdrawal: the report from the Polio Working Group-P. Figueroa

Progress towards interruption of wild poliovirus and persistent type 2 cVDPV and risk mitigation strategy-H. Jafari

Type 2 risk assessment and response strategy after OPV2 withdrawal-R. Sutter

Operationalizing IPV and bOPV introduction in priority countries-M. Zaffran


Show lessShow more

Session: Hepatitis E vaccine

Show lessShow more

Session: Vaccine hesitancy

Background documents

Report of the Working Group on vaccine hesitancy. Report provided to SAGE ahead of the October 2014 SAGE meeting

Revised report of the Working Group on vaccine hesitancy. The report was revised after the October 2014 SAGE meeting

Full report of annexes to the report on vaccine hesitancy 

Systematic review of strategies to address vaccine hesitancy

Systematic Review of Vaccine Hesitancy (website)

Presentations

Introduction-J. Eskola

Deliverables and conclusions-N. MacDonald

Recommendations-J. Eskola

Show less Show more